StemCell Therapy

SAN DIEGO, Aug. 8, 2017 /PRNewswire/ --AVACEN Medical (AVACEN) announced partnering with Morulaa HealthTech of Chennai, India to introduce its FDA-cleared AVACEN 100, Class II medical device, in India for treating the joint pain associated with Arthritis which is currently being used in the USA.

According to the World Health Organization, Arthritis affects approximately 200 million people in India. This prevalence is higher than many well-known diseases such as diabetes and cancer. This has a devastating impact on those who suffer from the arthritis and their personal support systems. In addition, arthritis imposes a large economic burden on public and private healthcare providers.

AVACEN recently received CE (Conformit Europenne) Mark approval to market the AVACEN 100 to the European Union's 28 member countries for treating the joint pain associated with Arthritis. AVACEN believes this is the first time a medical device has been approved for treating whole-body arthritis pain.

Currently used in the USA the AVACEN 100 uses an entirely new concept to treat Arthritis pain. It noninvasively and safely infuses heat into the circulatory system forcing the body to dilate peripheral capillaries to radiate off this excess heat.

AVACEN Medical CEO Thomas Muehlbauer described the AVACEN 100 as "the only medical device on the market today able to provide non-invasive, whole-body treatment, using a single point of contact. It is the ideal drug-free and safe alternative for rapid relief of arthritis pain from the inside". Muehlbauer added, "With approximately 2 million safe treatments, we frequently hear reports dramatic results such as being able to return to playing piano, gardening, and chopping vegetables. Even gnarled hand joints have been reported to disappear."

About AVACEN 100 Patents

The US Patent Office has issued 4 Patents to AVACEN which include apparatus claims directed to features of the Heat Therapy apparatus manufactured by AVACEN and method claims directed to specific methods of use, referred to by the company as the AVACEN Treatment Method. The patents also cover innovations embodied in the AVACEN 100 system, which is expected to allow multiple therapeutic uses to alleviate symptoms associated with a circulatory, neurological, lymphatic, or endocrinal dysfunction, or any combination thereof.

Patents have also been issued for China, Australia, Japan, UK, France, Germany, Spain, Sweden and Canada. Patents are pending in India and Hong Kong.

AboutAVACEN Medical

AVACEN Medical is dedicated to the innovation and design of safe, easy to use, noninvasive drug-free alternatives for wound-healing and the management of pain associated with numerous chronic and acute conditions including the temporary relief of minor muscle and joint pain and stiffness associated with arthritis and potentially other conditions that can cause joint pain, such as CRPS, Reynaud's, and Lyme Disease. Founded in 2009, AVACEN Medical is headquartered in San Diego. Contact: Ryan Jeffcoat at (888) 428-2236 x 711 or info@AVACEN.com.

About Morulaa HealthTech

Established by a family with over 100 years of experience in business, Morulaa HealthTech provides turnkey solutions for manufacturers and distributors in the Medical Device sectors. The unique Morulaa model for Product Registration and Distribution, uses in-house regulatory and marketing teams working in-sync with clients to commercialize healthcare products across India and South East Asia. Morulaa HealthTech currently has clients from America, Europe, Asia and Oceania. For more information: http://www.morulaa.com

IMPORTANT NOTES: The AVACEN 100 is not for sale in the U.S. or E.U. for any non-cleared or non-approved indication mentioned in this document.

E.U. CE-Approval: A heat therapy system indicated for the temporary relief of minormuscle and joint pain and stiffness; the temporary relief of joint pain associated witharthritis, muscle spasms, minor strains and sprains;the temporary relief of widespreadpain associated with fibromyalgia; muscular relaxation; andthe temporary increase ofmicrocirculation.

U.S. FDA-Clearance: A heat therapy system indicated for the temporary relief of minor muscle and joint pain and stiffness; the temporary relief of joint pain associated with arthritis; muscle spasms; minor strains and sprains; muscular relaxation; and the temporary increase of local circulation where applied.

View original content with multimedia:http://www.prnewswire.com/news-releases/avacen-medical-introduces-new-concept-for-treating-arthritis-pain-to-india-300501093.html

SOURCE AVACEN Medical

Follow this link:
AVACEN Medical Introduces New Concept for Treating Arthritis Pain to India - PR Newswire (press release)

This entry was posted on August 8, 2017 at 5:41 pm and is filed under Arthritis. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |